Nymox Pharmaceutical Corp SEC filings NYMXF
Nymox Pharmaceutical Corp has 408 filings in SEC EDGAR's recent list, going back to Aug 8, 1996. Its latest annual report, Form 20-F, was filed on Sep 14, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Aug 31, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| F-3 | Shelf registration (foreign issuer) | Mar 29, 2022 | — |
| 424B5 | Prospectus supplement | Mar 22, 2022 | — |
| F-3 | Shelf registration (foreign issuer) | Dec 9, 2021 | — |
| F-3 | Shelf registration (foreign issuer) | May 12, 2021 | — |
| 424B5 | Prospectus supplement | Aug 14, 2020 | — |
| 424B5 | Prospectus supplement | Aug 14, 2020 | — |
| 424B5 | Prospectus supplement | Jul 17, 2020 | — |
| F-3/A | Filing | May 6, 2020 | — |
| F-3/A | Form f-3/a | Apr 24, 2020 | — |
| F-3 | Shelf registration (foreign issuer) | Apr 3, 2020 | — |
| 424B5 | Prospectus supplement | Feb 9, 2016 | — |
| F-3/A | Amendment no. 1 to form f-3 registration statement | Jul 24, 2015 | — |
| F-3 | Shelf registration (foreign issuer) | Jul 14, 2015 | — |
| 424B3 | Prospectus | Mar 24, 2003 | — |
| POS AM | Amendment no. 6 to form f-1, filed on form f-3 | Mar 12, 2003 | — |
| POS AM | Form f-1 amendment no. 5 | Jul 30, 2002 | — |
| F-3 | Shelf registration (foreign issuer) | Apr 1, 2002 | — |
| POS AM | Post effective amendment #4 | Nov 9, 2001 | — |
| POS AM | Post-effective amendment 3 - nymox pharmaceutical | Aug 10, 2001 | — |
| 424B3 | Prospectus | Jun 1, 2001 | — |
| POS AM | Post effective amendment #2 | May 15, 2001 | — |
| POS AM | Post effective amendment no. 1 | May 8, 2001 | — |
| 424B3 | Prospectus | Feb 15, 2001 | — |
| 424B3 | Prospectus | Oct 12, 2000 | — |
| 424B3 | Prospectus | Aug 22, 2000 | — |
| F-1/A | Amendment no. 1 to form f-1 | Mar 9, 2000 | — |
| F-1 | Registration statement (foreign issuer) | Feb 29, 2000 | — |
Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NYMXF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Quebec Canada, Quebec, Canada
- SEC filer status
- Accelerated filer
- SEC CIK
- 1018735
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.